INDV Indivior Pharmaceuticals, Inc. Common Stock
XNAS
36.41
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
INDV
$36.41
—
What changed
Recent filings, trades and movesKey stats
$36.41
- 52-Week Range
- $27.68 – $42.81
- YTD
- +1.90%
- Straddle Price
- $9.85
- P/C Vol Ratio
- 0.18
- Market Cap
- $4.3B
- Open
- $35.43
- Day Range
- $35.32 – $37.02
- Volume
- 4,872,834
- Prev Close
- $35.37
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.98% |
| Beta vs SPY | 0.69 |
| Cost of Equity (CAPM) | 8.42% (VRP-adj) |
| WACC | 8.33% |
| Volatility Risk Premium | +72.5pp (IV − HV30) |
| Effective Tax Rate | 16.4% |
| Rev. Growth (YoY, DCF input) | -0.6% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | -750.0% |
| Book / Price | -1.3% |
| Gross Margin (TTM) | 84.9% |
| FCF Margin (TTM) | 2.2% |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $35.18 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $34.96 |
| Bollinger Width / SMA20 | 30.4% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $5B |
Peers used for multiples: AMRX, GKOS, JNJ, LGND, LLY, MRK, PTGX, VTRS
Blended Fair Value
$79.01
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $6.04 | 21% | |
| DDM (Gordon) | $90.08 | 0% | |
| Peer P/E | $285.97 | 10% | median 80.3× · 6 peers |
| Peer EV/EBITDA | $127.98 | 12% | median 28.1× · 7 peers |
| Peer P/B | n/a | 0% | median 10.0× · 8 peers |
| Peer P/S | $115.01 | 16% | median 10.6× · 8 peers |
| Market Anchor (SMA50) | $35.18 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $37.08 | 41% | 25 strikes · skew +0.26 |
As of 2026-11-03 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $4.3B
- Employees
- 838
- List Date
- 2014-12-24
- CIK
- 0001625297
- Last Earnings
- Oct 29 before open · +1.4% vs ±14.6% expected
- Headquarters
- North Chesterfield, VA
- Homepage
- https://www.indivior.com
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | 14.03% | -4.80% | -0.98% | 2.75% |
| Feb | -- | 23.44% | -21.23% | -6.51% | -1.43% |
| Mar | -- | -6.87% | -0.21% | -4.69% | -3.92% |
| Apr | -- | -16.50% | 22.71% | 20.00% | 8.74% |
| May | -- | 3.91% | 11.34% | -4.35% | 3.63% |
| Jun | 4.52% | -12.20% | 18.30% | 17.63% | 7.06% |
| Jul | -3.52% | -12.70% | 37.79% | -0.42% | 5.29% |
| Aug | -2.20% | -8.22% | 15.34% | -6.53% | -0.40% |
| Sep | 1.45% | -19.88% | -1.99% | 3.73% | -4.17% |
| Oct | -15.96% | -7.68% | 25.19% | -0.03% | 0.38% |
| Nov | -13.19% | 19.89% | 7.69% | 0.00%* | 3.60% |
| Dec | -9.21% | 10.69% | 6.79% | -- | 2.76% |
| Total | -33.73% | -21.46% | 171.23% | 14.98% | 32.76% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $34.96
SMA 50: $35.18
SMA 200: $35.68
Current: $36.28
EMA 12: $35.11
EMA 26: $35.16
MACD: -0.0591 | Signal: 0.1970
BEARISH
ADX (14): 24.02
WEAK TREND
+DI: 22.15
−DI: 14.33
Momentum Oscillators
RSI (14): 58.42
NEUTRAL
Stoch %K: 70.74
Stoch %D: 65.02
Williams %R: -15.71
Volume & Volatility
BB Upper: $36.82
BB Lower: $33.10
NEUTRAL
OBV: 139,009,815
Vol SMA 20: 2,934,063
Vol ROC: 114.07%
ATR: $1.26
True Range: $1.70
HV 20: 32.5%
HV 30: 29.5%
HV 60: 26.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-04T00:00:00 – 2026-11-02T00:00:00
AI Analysis
Written before INDV’s Oct 29 earnings report, so it doesn’t reflect the results.
Here is the comprehensive stock analysis report for INDV:
Executive Summary
BULLISH (Confidence Level: 7/10)
Key Drivers:
- Positive earnings momentum, with a strong IV rank indicating low volatility
- Strong technical signals from MACD and Stochastic %K/D
- Positive news sentiment from recent headlines
Primary Risks:
- Oversold RSI and stochastic oscillators may trigger a bounce or correction
- Low volume and institutional interest could lead to reduced market impact
Investment Thesis: INDV is poised for a continued uptrend, driven by strong earnings momentum and positive technical signals. However, the stock remains oversold and may experience a correction before resuming its upward trajectory.
Recent News Sentiment Impact: The recent headlines have been overwhelmingly positive, supporting the bullish case for INDV. The presentation of new real-world data at ASAM 2026 Annual Conference and the announcement of a quarterly earnings release have both contributed to the upbeat sentiment.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - Bullish, Medium-term (1-3 months) - Neutral
Support/Resistance Levels:
- Upper Bollinger Band: $40.67 (resistance)
- Middle Line (EMA 12): $37.46 (support)
Momentum Signals:
- MACD: Bullish
- Stochastic %K/D: Oversold, indicating a potential bounce or correction
- RSI: Neutral (54.86), but may be oversold in the short-term
Volume Analysis:
- Volume SMA 20: 2377736.30 (low volume)
- On-Balance Volume (OBV): 130107569.34 (accumulation)
News & Sentiment Analysis
Recent Headlines Summary:
- Positive news headlines from Indivior, including the presentation of new real-world data and quarterly earnings release
Sentiment Assessment: POSITIVE (Aggregate sentiment based on recent headlines)
Catalyst Identification:
- Upcoming quarterly earnings release on April 30th
Market Narrative: The positive news sentiment aligns with the bullish technical signals, supporting a continued uptrend.
Risk & Volatility Assessment
Risk Metrics:
- Beta: 0.64 (Low volatility)
- Alpha: 1.08 (Strong performance relative to market)
Volatility Regime: Low volatility - stock moves less than market
Options Market Signals:
- IV Rank: 14.3% (Low)
- Put/Call Volume Ratio: 1.34 (Bearish sentiment)
Downside Protection:
- Support levels: Middle Line (EMA 12) $37.46, Lower Bollinger Band $35.14
Market Context & Positioning
Sector Performance:
- Relative strength vs sector/market: INDV has been outperforming the market
Institutional Activity:
- Low volume and institutional interest may lead to reduced market impact
Correlation Analysis:
- Correlation with SPY: 0.19 (Low)
Relative Valuation:
- Position within trading range: Above upper Bollinger Band, indicating a potential correction or consolidation
Key Levels & Action Items
Critical Price Levels:
- Support: Middle Line (EMA 12) $37.46, Lower Bollinger Band $35.14
- Resistance: Upper Bollinger Band $40.67
Breakout/Breakdown Levels:
- Technical levels that could trigger significant moves: $38.00, $39.50, and $41.50
Time-Sensitive Catalysts:
- Upcoming quarterly earnings release on April 30th
Risk Management:
- Stop-loss levels: $35.14 (Lower Bollinger Band)
- Position sizing considerations: Consider reducing position size or hedging based on the oversold RSI and stochastic oscillators
Generated
News
All INDV news →
The company is merging with a peer.
Qelbree prescriptions surged 18% as revenue hit $226.8 million ahead of Indivior merger.
Earnings History
7 of 7 under expected move
Avg Expected Move
15.88%
Avg Actual Move
4.77%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-04-24 | After-Close | 22.30% | 7.43% | 0.33x | Within |
| 2025-07-31 | Pre-Market | 20.83% | 16.09% | 0.77x | Within |
| 2025-10-30 | After-Close | 11.59% | 0.82% | 0.07x | Within |
| 2026-02-26 | After-Close | 14.68% | 2.94% | 0.20x | Within |
| 2026-04-30 | After-Close | 12.51% | 2.39% | 0.19x | Within |
| 2026-08-04 | Pre-Market | 14.65% | 2.33% | 0.16x | Within |
| 2026-10-29 | Pre-Market | 14.60% | 1.38% | 0.09x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
INDV Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $9.85
7-DTE Move: $9.35
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 454
Put Volume: 84
P/C Volume: 0.185
BULLISH
Call OI: 11,094
Put OI: 11,763
P/C OI: 1.06
Total OI: 22,857
ATM Options Pricing
ATM Call: $0.40
ATM Put: $9.45
Call %: 1.1%
Put %: 26.0%
Chain Summary
Chain Volume: 538
Chain OI: 22,857
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 71st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
71%
vs own history
GEX tilt
+0.65
OI-weighted, today
Vanna tilt
+0.92
δ-sensitivity to IV
Charm tilt
-0.83
δ-decay vs time
Vanna tilt +0.92: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.83: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 13 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$9.85Nov 9
Beta Analysis
Risk Metrics
Beta: 0.6471
Alpha: 12.38%
Correlation: 0.2492
R-Squared: 6.2%
Stock Volatility: 33.3%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 246
Period: 252 trading days
Data Points: 246
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own INDV
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Oaktree Capital Asset manager Howard Marks | $251.4M | #5 of 130 | -12.3% | 13F | |
| Citadel Hedge fund Ken Griffin | $109.5M | #378 of 6285 | -25.4% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $86.1M | #391 of 3716 | -54.3% | 13F | |
| Point72 Hedge fund Steve Cohen | $51.3M | #321 of 1945 | +1217.3% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $2.8M | #619 of 997 | +83.6% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $251K | #2479 of 4729 | +97.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
INDV Institutional Ownership (13F)
Filings for 2026-06-30 · 127 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 126,750,000 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$102.09M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $55.67M | 54.53% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $37.23M | 36.46% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $4.82M | 4.72% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $1.26M | 1.23% | 2026-09-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $1.14M | 1.11% | 2026-06-30 |
| 6 | EQUITEC PROPRIETARY MARKETS, LLC | $1.08M | 1.05% | 2026-09-30 |
| 7 | UBS Group AG Custodian | $820.60K | 0.80% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $86.04K | 0.08% | 2026-09-30 |
8 filers$39.13M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | UBS Group AG Custodian | $20.52M | 52.42% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $9.85M | 25.17% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $3.43M | 8.78% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $2.49M | 6.37% | 2026-06-30 |
| 5 | EQUITEC PROPRIETARY MARKETS, LLC | $1.08M | 2.75% | 2026-09-30 |
| 6 | IMC-Chicago, LLC Custodian | $777.95K | 1.99% | 2026-09-30 |
| 7 | Simplex Trading, LLC Custodian | $602.28K | 1.54% | 2026-09-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $381.58K | 0.98% | 2026-06-30 |
INDV Insider Trading (Form 4)
Latest: 2026-08-27Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | Woodrow D Anderson | Chief Accounting Officer | Buy (P) | +1,500 | $35.69 | $53.5K | EDGAR |
| 2026-08-05 | Woodrow D Anderson | Chief Accounting Officer | Buy (P) | +1,500 | $36.28 | $54.4K | EDGAR |
| 2026-07-13 | Christian Heidbreder | Chief Scientific Officer | Sell (S) | −18,586 | $41.14 | -$764.6K | EDGAR |
| 2026-06-23 | Joseph Ciaffoni | Chief Executive Officer | Mixed Exer +1,266,903 · Tax −612,549 |
+654,354 | $38.32 | -$23.47M | EDGAR |
| 2026-06-12 | Christian Heidbreder | Chief Scientific Officer | Sell (S) | −18,586 | $38.06 | -$707.4K | EDGAR |
| 2026-06-10 | Ryan Preblick | Chief Financial Officer | Sell (S) | −36,000 | $37.70 | -$1.36M | EDGAR |
| 2026-05-14 | David E. Wheadon | Director | Award (A) | +10,430 | — | EDGAR | |
| 2026-05-14 | Daniel A Ninivaggi | Director | Award (A) | +6,518 | — | EDGAR | |
| 2026-05-14 | Barbara Ryan | Director | Award (A) | +6,518 | — | EDGAR | |
| 2026-05-14 | Juliet Thompson | Director | Mixed Tax −1,117 · Grant +6,518 |
+5,401 | $38.28 | -$42.8K | EDGAR |
| 2026-05-14 | Mark Stejbach | Director | Award (A) | +6,518 | — | EDGAR | |
| 2026-05-14 | Keith Humphreys | Director | Award (A) | +6,518 | — | EDGAR | |
| 2026-05-14 | Stuart A Kingsley | Director | Award (A) | +6,518 | — | EDGAR | |
| 2026-03-17 | Ryan Preblick | Chief Financial Officer | Mixed Tax −2,843 · Exer +6,302 |
+3,459 | $31.11 | -$88.4K | EDGAR |
| 2026-03-13 | Barbara Ryan | Director | Buy (P) | +8 | $31.09 | $249 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
INDV Insider Holdings
13 insiders · @ $36.28
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Joseph Ciaffoni | Chief Executive Officer | 790,330 | $28.67M | $0 | 2 | 2026-06-23 |
| 2 | Ryan Preblick | Chief Financial Officer | 284,751 | $10.33M | -$1.36M | 4 | 2026-06-10 |
| 3 | Christian Heidbreder | Chief Scientific Officer | 209,337 | $7.59M | -$1.47M | 4 | 2026-07-13 |
| 4 | Jeffrey W Burris | Chief Legal Officer | 71,518 | $2.59M | $0 | 2 | 2026-03-05 |
| 5 | Patrick A Barry | Chief Commercial Officer | 31,380 | $1.14M | $0 | 1 | 2026-02-12 |
| 6 | David E. Wheadon | Director | 30,780 | $1.12M | $62.7K | 3 | 2026-05-14 |
| 7 | Woodrow D Anderson | Chief Accounting Officer | 27,638 | $1.00M | $108.0K | 4 | 2026-08-27 |
| 8 | Daniel A Ninivaggi | Director | 27,163 | $985.5K | $27.4K | 3 | 2026-05-14 |
| 9 | Mark Stejbach | Director | 27,087 | $982.7K | $27.4K | 3 | 2026-05-14 |
| 10 | Juliet Thompson | Director | 18,748 | $680.2K | $0 | 2 | 2026-05-14 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
INDV Board & Officers
As of SEC filings through Nov 4, 2026Directors 12
- Barbara Ryan · since Jan 1, 2026
- Daniel A Ninivaggi · since Jan 1, 2026
- David E. Wheadon · since Jan 1, 2026
- Joseph Ciaffoni · since Jan 1, 2026
- Juliet Thompson · since Jan 1, 2026
- Keith Humphreys · since Jan 1, 2026
- Mark Stejbach · since Jan 1, 2026
- Stuart A Kingsley · since Jan 1, 2026
- Bethany Sensenig · since Nov 2, 2026
- Carrolee Barlow · since Nov 2, 2026
- Georges Gemayel · since Nov 2, 2026
- Jack A. Khattar · since Nov 2, 2026
Officers 10
- Jack A. Khattar · Chief Executive Officer · since Nov 2, 2026
- Timothy C Dec · SVP, Chief Financial Officer · since Nov 2, 2026
- Christian Heidbreder · Chief Scientific Officer · since Jan 1, 2026
- Jeffrey W Burris · Chief Legal Officer · since Jan 1, 2026
- Patrick A Barry · Chief Commercial Officer · since Jan 1, 2026
- Woodrow D Anderson · Chief Accounting Officer · since Jan 1, 2026
- Frank Mottola · SVP, Chief Tech. Ops. Officer · since Nov 2, 2026
- Jonathan Rubin · SVP, Chief Medical Officer · since Nov 2, 2026
- Padmanabh P. Bhatt · SVP, Chief Scientific Officer · since Nov 2, 2026
- William Todd Horich · SVP, Chief Commercial Officer · since Nov 2, 2026
Changes in the last 10 years (26)
| Nov 2, 2026 | William Todd Horich became SVP, Chief Commercial Officer |
| Nov 2, 2026 | Timothy C Dec became SVP, Chief Financial Officer |
| Nov 2, 2026 | The company announced the departure of Ryan Preblick as Chief Financial Officer in an SEC filing |
| Nov 2, 2026 | The company announced the departure of Joseph Ciaffoni as Chief Executive Officer in an SEC filing |
| Nov 2, 2026 | Padmanabh P. Bhatt became SVP, Chief Scientific Officer |
| Nov 2, 2026 | Jonathan Rubin became SVP, Chief Medical Officer |
| Nov 2, 2026 | Jack A. Khattar became a director |
| Nov 2, 2026 | Jack A. Khattar became Chief Executive Officer |
| Nov 2, 2026 | Georges Gemayel became a director |
| Nov 2, 2026 | Frank Mottola became SVP, Chief Tech. Ops. Officer |
| Nov 2, 2026 | Carrolee Barlow became a director |
| Nov 2, 2026 | Bethany Sensenig became a director |
| Jan 1, 2026 | Woodrow D Anderson became Chief Accounting Officer |
| Jan 1, 2026 | Stuart A Kingsley became a director |
| Jan 1, 2026 | Ryan Preblick became Chief Financial Officer |
| Jan 1, 2026 | Patrick A Barry became Chief Commercial Officer |
| Jan 1, 2026 | Mark Stejbach became a director |
| Jan 1, 2026 | Keith Humphreys became a director |
| Jan 1, 2026 | Juliet Thompson became a director |
| Jan 1, 2026 | Joseph Ciaffoni became a director |
| Jan 1, 2026 | Joseph Ciaffoni became Chief Executive Officer |
| Jan 1, 2026 | Jeffrey W Burris became Chief Legal Officer |
| Jan 1, 2026 | David E. Wheadon became a director |
| Jan 1, 2026 | Daniel A Ninivaggi became a director |
| Jan 1, 2026 | Christian Heidbreder became Chief Scientific Officer |
| Jan 1, 2026 | Barbara Ryan became a director |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
INDV Proposed Insider Sales (Form 144)
Latest: 2026-07-10
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-10 | Heidbreder Christian | Officer | 18,586 | $764.6K | 2026-07-10 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-11 | Heidbreder Christian | Officer | 18,586 | $707.4K | 2026-06-11 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-08 144/A | Preblick Ryan | Officer | 36,000 | $1.36M | 2026-06-08 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-11-07 | Cetani Cynthia C | Officer | 121,737 | $3.73M | 2025-11-07 | Stifel Nicolaus & Company Inc | — | EDGAR |
| 2025-09-08 | Crossley Mark | Affiliate | 26,463 | $655.0K | 2025-09-08 | Merrill Lynch, Pierce, Fenner & … | — | EDGAR |
| 2025-09-08 | Mark Crossley | affiliate | 183,938 | $4.59M | 2025-09-08 | J.P. Morgan Securities LLC | — | EDGAR |
| 2025-09-04 | Mark Crossley | affiliate | 30,000 | $744.0K | 2025-09-04 | J.P. Morgan Securities LLC | — | EDGAR |
| 2025-08-28 | Mark Crossley | affiliate | 52,320 | $1.28M | 2025-08-28 | J.P. Morgan Securities LLC | — | EDGAR |
| 2024-03-20 | Heidbreder Christian | Officer | 6,284 | $132.4K | 2024-03-13 | Global Shares Execution Services… | — | EDGAR |
| 2024-03-14 | Cetani Cynthia C | Officer | 66,073 | $1.39M | 2024-03-14 | Stifel Nicolaus & Company Inc. | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-03
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-03 | Other events | EDGAR |
| 2026-11-02 | Material agreement · Acquisition or sale completed · New debt obligation · Director or officer change · Bylaws or fiscal year change · Regulation FD disclosure | EDGAR |
| 2026-10-29 | Earnings results | EDGAR |
| 2026-10-15 | Shareholder vote results | EDGAR |
| 2026-10-06 | Other events | EDGAR |
| 2026-09-17 | Regulation FD disclosure · Other events | EDGAR |
| 2026-09-15 | Agreement terminated | EDGAR |
| 2026-08-03 | Regulation FD disclosure | EDGAR |
| 2026-08-03 | Earnings results · Regulation FD disclosure | EDGAR |
| 2026-08-03 | Material agreement · Regulation FD disclosure | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
39 ETFs hold INDV
25 shown · $434.77M total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $134.4M | — | 2026-09-30 |
| 2 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.05% | $95.3M | — | 2026-09-30 |
| 3 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.12% | $53.0M | — | 2026-09-30 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.05% | $47.7M | — | 2026-09-30 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.14% | $25.0M | — | 2026-09-30 |
| 6 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.09% | $20.3M | — | 2026-08-31 |
| 7 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.25% | $15.0M | — | 2026-09-30 |
| 8 | VHT Vanguard Health Care ETF | Vanguard | 0.05% | $11.4M | — | 2026-09-30 |
| 9 | PSC Principal U.S. Small-Cap ETF | Nport | 0.31% | $7.2M | — | 2026-06-30 |
| 10 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.25% | $4.2M | — | 2026-09-30 |
| 11 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $3.6M | — | 2026-09-30 |
| 12 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.94% | $3.4M | — | 2026-08-31 |
| 13 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.01% | $2.6M | — | 2026-08-31 |
| 14 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.26% | $1.8M | — | 2026-08-31 |
| 15 | SIXS ETC 6 Meridian Small Cap Equity ETF | Nport | 1.14% | $1.6M | — | 2026-08-31 |
| 16 | JHSC John Hancock Multifactor Small Cap ETF | Nport | 0.19% | $1.3M | — | 2026-06-30 |
| 17 | EZM WisdomTree U.S. MidCap Fund | Nport | 0.14% | $1.3M | — | 2026-06-30 |
| 18 | SIXL ETC 6 Meridian Low Beta Equity Strategy ETF | Nport | 0.45% | $911,079 | — | 2026-08-31 |
| 19 | SEIS SEI Select Small Cap ETF | Nport | 0.15% | $879,355 | — | 2026-06-30 |
| 20 | TILT FlexShares Morningstar US Market Factor Tilt Index Fund | Nport | 0.04% | $853,413 | — | 2026-07-31 |
| 21 | SMIZ Zacks Small/Mid Cap ETF | Nport | 0.26% | $721,025 | — | 2026-08-31 |
| 22 | ROSC Hartford Multifactor Small Cap ETF | Nport | 1.10% | $674,609 | — | 2026-07-31 |
| 23 | QVMS Invesco S&P SmallCap 600 QVM Multi-Factor ETF | Nport | 0.27% | $659,723 | — | 2026-08-31 |
| 24 | GVLU Gotham 1000 Value ETF | Nport | 0.25% | $579,426 | — | 2026-06-30 |
| 25 | OPTZ Optimize Strategy Index ETF | Nport | 0.20% | $561,578 | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$3.56
TTM Revenue
$1.37B
TTM Net Income
$450.00M
TTM Op. Cash Flow
$95.00M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $356.00M | $137.00M | $1.12 | $96.00M |
| Q2 '26 | 2026-06-30 | $343.00M | $122.00M | $0.98 | $230.00M |
| Q1 '26 | 2026-03-31 | $317.00M | $89.00M | $0.69 | $-10.00M |
| Q4 '25 | 2025-12-31 | $358.00M | $102.00M | $0.79 | $-221.00M |
| Q3 '25 | 2025-09-30 | $314.00M | $42.00M | $0.33 | $-38.00M |
| Q2 '25 | 2025-06-30 | $302.00M | $18.00M | $0.14 | $160.00M |
| Q1 '25 | 2025-03-31 | $266.00M | $47.00M | $0.38 | $73.00M |
| Q4 '24 | 2024-12-31 | $299.00M | $21.00M | $0.16 | $-17.00M |
| Q3 '24 | 2024-09-30 | $307.00M | $22.00M | $0.16 | $2.00M |
| Q2 '24 | 2024-06-30 | $299.00M | $-97.00M | $-0.72 | $88.00M |
| Q1 '24 | 2024-03-31 | $284.00M | $61.00M | $0.45 | $-37.00M |
| Q4 '23 | 2023-12-31 | — | — | — | — |
Q3 2026 • period ending 2026-09-30 • filed 2026-10-29
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
0.00
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
—
ROA
28.8%
Div Yield
0.00%
FCF Yield
—
Debt/Equity
—
Current Ratio
—
Market Cap
$0.00
as of 2026-11-03
INDV vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 46.0 | +45.5% | +31.3% | 27 |
| ABBV ABBVIE INC. | $514.9B | 50.6 | +10.7% | +28.1% | 34 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.5% | 56 |
| ISRG Intuitive Surgical Inc. | $160.0B | 55.8 | +20.5% | −17.9% | 18 |
| RVMD Revolution Medicines, Inc. Common Stock | $41.6B | — | — | +151.5% | 66 |
| RYTM Rhythm Pharmaceuticals, Inc. Common Stoc | $7.8B | — | +61.0% | +8.3% | 64 |
| PTCT PTC Therapeutics, Inc. | $5.5B | — | −35.1% | −15.0% | 12 |
| INDV Indivior Pharmaceuticals, Inc. Common St | $4.3B | 10.2 | +16.3% | +1.5% | 21 |
| INVA Innoviva, Inc. Common Stock | $1.4B | 11.9 | +12.8% | −4.4% | 100 |
| Peer median | $100.8B | 48.3 | +12.8% | +18.2% | 45 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.41M
SI % of Float
8.08%
Days to Cover
3.38
Short Vol Ratio
58.5%
Free Float
116.56M
Float %
98.8%
Short interest 2026-10-15 • Short volume 2026-11-02 • Float 2026-08-24